153 related articles for article (PubMed ID: 9811481)
21. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: an effective strategy to improve antinociceptive activity of neurotoxin.
Ruan Y; Yao L; Zhang B; Zhang S; Guo J
Drug Dev Ind Pharm; 2012 Jan; 38(1):123-8. PubMed ID: 21721852
[TBL] [Abstract][Full Text] [Related]
22. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Eur J Pharm Biopharm; 2008 Sep; 70(1):75-84. PubMed ID: 18472255
[TBL] [Abstract][Full Text] [Related]
23. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
24. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
25. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity.
Rempe R; Cramer S; Hüwel S; Galla HJ
Biochem Biophys Res Commun; 2011 Mar; 406(1):64-9. PubMed ID: 21295549
[TBL] [Abstract][Full Text] [Related]
26. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.
Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J
Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158
[TBL] [Abstract][Full Text] [Related]
27. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
28. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns.
Göppert TM; Müller RH
J Drug Target; 2005 Apr; 13(3):179-87. PubMed ID: 16036306
[TBL] [Abstract][Full Text] [Related]
29. Nanoparticle technology for drug delivery across the blood-brain barrier.
Lockman PR; Mumper RJ; Khan MA; Allen DD
Drug Dev Ind Pharm; 2002 Jan; 28(1):1-13. PubMed ID: 11858519
[TBL] [Abstract][Full Text] [Related]
30. In vitro release performance and analgesic activity of endomorphin-1 loaded nanoparticles.
Liu H; Ni J; Wang R
Pharmazie; 2006 May; 61(5):450-2. PubMed ID: 16724544
[TBL] [Abstract][Full Text] [Related]
31. Interaction of surfactant coated PLGA nanoparticles with in vitro human brain-like endothelial cells.
Moya ELJ; Lombardo SM; Vandenhaute E; Schneider M; Mysiorek C; Türeli AE; Kanda T; Shimizu F; Sano Y; Maubon N; Gosselet F; Günday-Türeli N; Dehouck MP
Int J Pharm; 2022 Jun; 621():121780. PubMed ID: 35504427
[TBL] [Abstract][Full Text] [Related]
32. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle.
Lu W; Wan J; She Z; Jiang X
J Control Release; 2007 Mar; 118(1):38-53. PubMed ID: 17240471
[TBL] [Abstract][Full Text] [Related]
33. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.
Gulyaev AE; Gelperina SE; Skidan IN; Antropov AS; Kivman GY; Kreuter J
Pharm Res; 1999 Oct; 16(10):1564-9. PubMed ID: 10554098
[TBL] [Abstract][Full Text] [Related]
34. [Polysorbate-80 modified neurotoxin nanoparticle with its transport and cytotoxicity against blood-brain barrier].
Zhao YM; Xia AX; Wei YH; Ruan YP; Li FZ
Yao Xue Xue Bao; 2010 Oct; 45(10):1312-6. PubMed ID: 21348312
[TBL] [Abstract][Full Text] [Related]
35. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
36. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Ulbrich K; Hekmatara T; Herbert E; Kreuter J
Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
[TBL] [Abstract][Full Text] [Related]
37. Opioid peptide drug development: transport of opioid chimeric peptides through the blood-brain barrier.
Pardridge WM
NIDA Res Monogr; 1992; 120():153-68. PubMed ID: 1501684
[TBL] [Abstract][Full Text] [Related]
38. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
39. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
Kreuter J
J Nanosci Nanotechnol; 2004 May; 4(5):484-8. PubMed ID: 15503433
[TBL] [Abstract][Full Text] [Related]
40. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
Gao K; Jiang X
Int J Pharm; 2006 Mar; 310(1-2):213-9. PubMed ID: 16426779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
